Quarterly report pursuant to Section 13 or 15(d)

Revenues - Additional Information (Detail)

v3.7.0.1
Revenues - Additional Information (Detail)
 3 Months Ended 6 Months Ended
Feb. 27, 2017
USD ($)
Jan. 04, 2017
USD ($)
Jan. 04, 2017
EUR (€)
Jun. 30, 2017
USD ($)
Product
Jun. 30, 2016
USD ($)
Jun. 30, 2017
USD ($)
Product
Jun. 30, 2017
EUR (€)
Jun. 30, 2016
USD ($)
Dec. 31, 2016
USD ($)
Deferred Revenue Arrangement [Line Items]                  
Revenues from product sales           $ 0      
Non-current deferred revenue       $ 60,784,291   60,784,291     $ 1,409,483
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, revenue recognized         $ 1,100,000     $ 2,300,000  
Deferred revenue       2,700,000 5,100,000 2,700,000   5,100,000  
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Upfront Payment Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, license upfront payment           6,500,000      
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Research Services [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, revenue recognized       800,000   $ 1,800,000      
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Research Services [Member] | Extension Term [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Research collaboration agreement, estimated period           5 years 5 years    
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Contractual agreement, potential payments       424,600,000   $ 424,600,000      
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Contractual agreement, potential payments       295,500,000   295,500,000      
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Sales Milestone Payments [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Contractual agreement, potential payments       125,300,000   125,300,000      
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Upfront Payment Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Total allocable arrangement consideration           32,000,000 € 30,000,000    
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Deferred revenue       $ 3,500,000   $ 3,500,000      
Period after effective date agreements may be terminated           12 months 12 months    
Contract termination advance notice period           180 days 180 days    
Number of collaboration products | Product       4   4      
Number of worldwide collaboration products | Product       2   2      
Non-current deferred revenue       $ 30,100,000   $ 30,100,000      
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, license upfront payment   $ 32,000,000 € 30,000,000            
Collaboration agreement, revenue recognized       400,000 $ 0 $ 700,000   $ 0  
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Maximum [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Contract termination due to material breach, advance notice period           120 days 120 days    
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Minimum [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Contract termination due to material breach, advance notice period           90 days 90 days    
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Future Lead Product [Member] | Maximum [Member] | Sales Milestone Payments [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Contractual agreement, potential payments | €     515,000,000            
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Future Lead Product [Member] | Maximum [Member] | Research, Development And Commercial Milestones [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Contractual agreement, potential payments | €     569,000,000            
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Other Programs [Member] | Maximum [Member] | Research, Development And Commercial Milestones [Member] | Substantive [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Contractual agreement, potential payments | €     € 163,000,000            
ASKA Pharmaceutical Co Ltd [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Deferred revenue       2,930,000   $ 2,930,000      
Total allocable arrangement consideration $ 2,750,000                
Evaluation Period 60 days                
ASKA Pharmaceutical Co Ltd [Member] | Upfront Payment Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Upfront option payment $ 2,750,000                
ASKA Pharmaceutical Co Ltd [Member] | Collaborative Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments       0   0      
AstraZeneca [Member] | Upfront Payment Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, revenue recognized       600,000   600,000      
AstraZeneca [Member] | Collaborative Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Deferred revenue       19,000,000   19,000,000      
Non-current deferred revenue       27,400,000   $ 27,400,000      
AstraZeneca [Member] | License and Collaboration Agreement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Period after effective date agreements may be terminated           12 months 12 months    
Contract termination advance notice period           90 days 90 days    
Contract termination due to material breach, advance notice period           180 days 180 days    
Contract termination advance notice period if marketing approval obtained           180 days 180 days    
Contract termination due to Payment breach, advance notice period           30 days 30 days    
Contract termination due to material breach, additional notice period if the breach is not susceptible           180 days 180 days    
Collaborative arrangement license description           (i) research and development license for the Lead Product, (ii) commercial license for the Lead Product, (iii) individual research licenses for each of the four AstraZeneca Collaboration Products, (iv) individual commercial licenses for each of the four AstraZeneca Collaboration Products, and (v) individual non-exclusive platform technology licenses for the Lead Product and the four AstraZeneca Collaboration Products. (i) research and development license for the Lead Product, (ii) commercial license for the Lead Product, (iii) individual research licenses for each of the four AstraZeneca Collaboration Products, (iv) individual commercial licenses for each of the four AstraZeneca Collaboration Products, and (v) individual non-exclusive platform technology licenses for the Lead Product and the four AstraZeneca Collaboration Products.    
AstraZeneca [Member] | License and Collaboration Agreement [Member] | Upfront Payment Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Total allocable arrangement consideration           $ 45,000,000      
AstraZeneca [Member] | License and Collaboration Agreement [Member] | Upfront Payment Arrangement [Member] | Estimated Development and Manufacturing Services [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Total allocable arrangement consideration           8,000,000      
AstraZeneca [Member] | License and Collaboration Agreement [Member] | Upfront Payment Arrangement [Member] | Relative Selling Price Method [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Total allocable arrangement consideration           53,200,000      
AstraZeneca [Member] | License and Collaboration Agreement [Member] | Maximum [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Contractual agreement, potential payments       45,000,000   45,000,000      
AstraZeneca [Member] | License and Collaboration Agreement [Member] | Maximum [Member] | Development Milestones [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Contractual agreement, potential payments       1,100,000,000   1,100,000,000      
AstraZeneca [Member] | License and Collaboration Agreement [Member] | Maximum [Member] | Sales Milestone Payments [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Contractual agreement, potential payments       $ 1,000,000,000   1,000,000,000      
AstraZeneca [Member] | Substantive Development and Sales Milestone [Member] | Maximum [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments           611,400,000      
AstraZeneca [Member] | Substantive Development and Sales Milestone [Member] | Minimum [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments           72,200,000      
AstraZeneca [Member] | Non Substantive Development and Sales Milestones [Member] | Maximum [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments           1,000,000,000      
AstraZeneca [Member] | Non Substantive Development and Sales Milestones [Member] | Minimum [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments           366,200,000      
AstraZeneca [Member] | Sales Milestones [Member] | Maximum [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments           $ 1,000,000,000